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Introduction {#sec001}
============

From early stage, Parkinson's disease (PD) patients suffer from various non-motor symptoms (NMS) as well as classic motor symptoms, and NMS can impact the quality of life even more than motor symptoms as the disease progresses \[[@pone.0162254.ref001]--[@pone.0162254.ref003]\]. Usually subtypes of PD are determined by main motor symptoms \[[@pone.0162254.ref004]\], and it is well-known that PD patients with non-tremor dominant (NTD) subtype show more severe motor symptoms and aggressive disease progression than those with tremor-dominant (TD) subtype \[[@pone.0162254.ref005], [@pone.0162254.ref006]\]. Similarly, NMS could be regarded to be more severe in PD patients with NTD subtype than those with TD subtype. Although previous studies already reported the difference in some NMS among PD subtypes, but these previous studies focused only few specific NMS among PD subtypes, not the whole spectrum of non-motor involvement \[[@pone.0162254.ref007]--[@pone.0162254.ref010]\]. Recently, there was only one study with systematic assessment of whole spectrum of NMS among PD subtypes, but this study investigated only the number of involved NMS among the PD subtypes, not the severity of NMS \[[@pone.0162254.ref011]\].

Furthermore, most of previous studies enrolled PD patients irrespective of PD medication, and failed to eliminate the confounding effects from medications \[[@pone.0162254.ref007]--[@pone.0162254.ref011]\]. Considering that dopaminergic medications have various effects on NMS in PD patients \[[@pone.0162254.ref012]\], confounding effects from medications should be considered during the investigation of motor or NMS in PD patients. Only few studies enrolled drug-naïve PD patients, but these studies mainly focused on premotor NMS, not the whole pattern of non-motor involvement in relation to the PD subtypes \[[@pone.0162254.ref013], [@pone.0162254.ref014]\].

In this study, to elucidate the characteristic non-motor features of each PD subtype, we investigated the whole pattern of NMS in drug-naïve PD patients, and compared between subtypes.

Methods {#sec002}
=======

Subjects {#sec003}
--------

This study was approved by the Institutional Review Board of each involved hospital, and all enrolled subjects provided written informed consent. We conducted nation-wide observational study to compare NMS between PD subtypes in drug-naïve PD patients.

We enrolled drug-naïve, early PD patients (disease duration of less than 4 years) and age- and sex-matched normal controls at movement disorders clinics in 40 community-based hospitals in Korea from May 2012 to December 2012. All PD patients were diagnosed with the United Kingdom Parkinson's Disease Society Brain Bank criteria \[[@pone.0162254.ref015]\], and divided into two subgroups based on the PD subtype for the main motor symptoms: tremor dominant (TD) subtype and non-tremor dominant (NTD) subtype (indeterminate subtype and postural instability and gait disturbance subtype) \[[@pone.0162254.ref004]\].

Subjects with structural brain lesions, other known neurodegenerative disease, cognitive impairment (mini-mental state examination score of \< 20 or fulfillment of *DSM-IV* criteria for dementia), psychiatric disorders needing medication, malignancy, or joint problems mimicking parkinsonism were excluded.

Clinical assessment {#sec004}
-------------------

Demographic and clinical data, including scales, were collected by interview and examination with movement disorder specialists at each hospital. Motor symptoms were evaluated with the Unified Parkinson Disease Rating Scale (UPDRS) part 3 and the Hoehn and Yahr (HY) scale \[[@pone.0162254.ref016]\]. Whole pattern of non-motor involvements were assessed by the Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's disease \[[@pone.0162254.ref017]\], and each NMS was also assessed with symptom-specific scales, including the Korean version of the Montreal Cognitive Assessment (MoCA-K) and Frontal Assessment Battery for cognitive evaluation \[[@pone.0162254.ref018], [@pone.0162254.ref019]\]; the Neuropsychiatric Inventory, Beck Depression Inventory (BDI) and Beck's Anxiety Inventory (BAI) for neuropsychiatric assessment \[[@pone.0162254.ref020]--[@pone.0162254.ref022]\]; and the PD sleep scale (PDSS) and Parkinson Fatigue Scale (PFS) for sleep and fatigue evaluation \[[@pone.0162254.ref023], [@pone.0162254.ref024]\].

Statistical analysis {#sec005}
--------------------

All data were presented as mean and standard deviation. Demographic and clinical data were compared between groups (normal controls and PD patients; TD and non-TD subtypes) by using independent t-test or Mann-Whitney U-test for continuous variables, and Pearson's χ^2^ or Fisher's exact test for categorical variables. To investigate characteristic NMS related to PD subtype, multivariate analysis was carried out with logistic regression model with demographic and clinical variables including motor and NMS. The results of logistic regression were presented using 95% confidence intervals (CIs). *p*-values \< 0.05 were considered statistically significant. Statistical analyses were performed with a commercially available software package (PASW version 18.0; SPSS Inc., Chicago, IL, USA).

Results {#sec006}
=======

Comparison of non-motor symptoms between PD patients and normal controls {#sec007}
------------------------------------------------------------------------

We enrolled 136 drug-naïve patients with early stage PD and 50 normal control subjects. Demographic and clinical data of all subjects were shown in [Table 1](#pone.0162254.t001){ref-type="table"}. Compared with normal controls, PD patients reported higher total NMSS score, and subscores of mood/cognition, gastrointestinal tract, unexplained pain, change in ability to taste or smell, and weight change ([Table 2](#pone.0162254.t002){ref-type="table"}). Similarly, PD patients also complained of more mood/cognitive symptoms (higher scores on the BAI, and lower MoCA-K scores) than normal controls.

10.1371/journal.pone.0162254.t001

###### Demographic characteristics of enrolled subjects.

![](pone.0162254.t001){#pone.0162254.t001g}

                            Parkinson's disease patients   Normal Control (n = 50)   *p*[^a^](#t001fn002){ref-type="table-fn"}   *p*[^b^](#t001fn003){ref-type="table-fn"}             
  ------------------------- ------------------------------ ------------------------- ------------------------------------------- ------------------------------------------- --------- -------
  Age, years                65.1 ± 8.7                     65.1 ± 8.6                65.2 ± 8.9                                  65.4 ± 8.0                                  0.941     0.963
  Sex, male, n (%)          58 (42.6)                      32 (47.1)                 26 (38.2)                                   17 (34)                                     0.315     0.386
  BMI, UD/NR/OW/OB, n       8/41/35/52                     5/20/18/25                3/21/17/27                                                                                        0.913
  Education, years          10.5 ± 4.6                     10.7 ± 4.7                9.4 ± 4.8                                   10.3 ± 3.4                                  0.829     0.225
  Disease duration, month   14.8 ± 11.7                    15.4 ± 11.6               14.2 ± 11.9                                                                                       0.500
  HY stage 1/2/3, n (%)     57/76/3 (41.9/55.9/2.2)        29/38/1 (42.6/55.9/1.5)   28/38/2 (41.2/55.9/2.9)                                                                           0.642
  UPDRS part 3              16.6 ± 8.0                     16.3 ± 8.7                16.7 ± 7.4                                  1.0 ± 2.1                                   \<0.001   0.476

PD, Parkinson's disease; BMI, body mass index; UD, underweight; NR, normal range; OW, overweight; OB, obese; HY, Hoehn and Yahr; UPDRS, Unified Parkinson's Disease Rating Scale.

^a^ comparison between PD and normal control.

^b^ comparison between tremor dominant and non-tremor dominant subtypes.

10.1371/journal.pone.0162254.t002

###### Comparisons of non-motor symptoms between Parkinson's disease patients and normal controls.
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                                             PD patients (n = 136)   Normal controls (n = 50)   *p*
  ------------------------------------------ ----------------------- -------------------------- -------
  **Non-Motor Symptoms Assessment Scale**                                                       
  Total score                                19.9 ± 19.4             13.9 ± 19.7                0.008
  Cardiovascular including falls             0.7 ± 1.5               0.8 ± 2.1                  0.297
  Sleep/fatigue                              3.1 ± 4.5               2.6 ± 4.1                  0.235
  Mood/cognition                             4.2 ± 6.7               1.8 ± 3.4                  0.003
  Perceptual problems/hallucinations         0.1 ± 0.9               0.3 ± 1.6                  0.118
  Attention/memory                           1.9 ± 2.6               1.8 ± 2.7                  0.389
  Gastrointestinal tract                     1.4 ± 2.8               0.9 ± 2.7                  0.018
  Urinary                                    3.8 ± 5.6               2.8 ± 4.5                  0.107
  Sexual function                            2.3 ± 5.3               1.9 ± 5.3                  0.141
  Unexplained pain                           0.7 ± 1.8               0.2 ± 0.8                  0.006
  Change in ability to taste or smell        1.0 ± 2.1               0.4 ± 1.1                  0.003
  Weight change (not related to diet)        0.3 ± 1.3               0.1 ± 0.6                  0.035
  Excessive sweat (not related to weather)   0.5 ± 1.8               0.3 ± 1.1                  0.411
  **Other Scales on Non-motor Symptoms**                                                        
  Parkinson's Disease Sleep Scale            125.4 ± 23.8            122.4 ± 25.3               0.299
  Parkinson Fatigue Scale                    34.5 ± 17.3             29.9 ± 26.2                0.010
  Beck Depression Inventory                  7.8 ± 7.0               7.1 ± 6.7                  0.230
  Beck Anxiety Inventory                     7.1 ± 7.5               5.7 ± 7.7                  0.003
  MoCA-K                                     24.3 ± 3.9              25.9 ± 3.1                 0.010

PD, Parkinson's disease; TD, tremor dominant subtype; NTD, non-tremor dominant subtype; MoCA-K, Korean version of the Montreal Cognitive Assessment.

Comparison of non-motor symptoms between PD subtypes {#sec008}
----------------------------------------------------

Of 136 enrolled PD patients, 68 subjects were PD patients with the TD subtype and 68 were those with the NTD subtype. Although the demographic and clinical data did not differ significantly between two PD subtypes, PD patients with NTD subtype patients showed higher total NMSS score and the only subscore of weight change domain comparing with those with TD subtype ([Table 3](#pone.0162254.t003){ref-type="table"}). In addition, there were no significant differences in PDSS, PFS, BDI, BAI, MoCA-K score.

10.1371/journal.pone.0162254.t003

###### Comparison of non-motor symptoms between subtypes of drug naïve Parkinson's disease.
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                                             TD (n = 68)    NTD (n = 68)   *p*
  ------------------------------------------ -------------- -------------- -------
  **Non-motor Symptom Scale**                                              
  Total score                                17.0 ± 20.8    23.0 ± 17.7    0.003
  Cardiovascular including falls             0.7 ± 1.7      0.7 ± 1.4      0.600
  Sleep/fatigue                              2.8 ± 4.6      3.3 ± 4.5      0.300
  Mood/cognition                             4.1 ± 8.0      4.4 ± 5.2      0.179
  Perceptual problems/hallucinations         0.2 ± 1.2      0.1 ± 0.6      0.493
  Attention/memory                           1.4 ± 2.2      2.3 ± 2.8      0.057
  Gastrointestinal tract                     1.3 ± 2.8      1.6 ± 2.7      0.107
  Urinary                                    3.3 ± 4.2      4.4 ± 6.7      0.384
  Sexual function                            1.7 ± 4.6      2.9 ± 6.0      0.189
  Unexplained pain                           0.5 ± 1.4      0.9 ± 2.2      0.246
  Change in ability to taste or smell        0.7 ± 1.7      1.3 ± 2.5      0.059
  Weight change (not related to diet)        0.1 ± 0.3      0.5 ± 1.8      0.031
  Excessive sweat (not related to weather)   0.3 ± 1.1      0.7 ± 2.3      0.300
  **Other Scales on Non-motor Symptoms**                                   
  Parkinson's Disease Sleep Scale            122.0 ± 27.7   128.8 ± 18.9   0.303
  Parkinson Fatigue Scale                    32.5 ± 16.7    36.3 ± 17.7    0.288
  Beck Depression Inventory                  6.9 ± 6.8      8.6 ± 7.2      0.122
  Beck Anxiety Inventory                     6.4 ± 6.8      7.8 ± 8.2      0.333
  MoCA-K                                     24.4 ± 4.0     24.3 ± 3.9     0.873

TD, tremor dominant subtype; NTD, non-tremor dominant subtype; MoCA-K, Korean version of the Montreal Cognitive Assessment.

Characteristic non-motor symptom associated with PD subtype {#sec009}
-----------------------------------------------------------

To elucidate the characteristic NMS in PD subtype, multivariate logistic regression analysis was done with PD subtype as the dependent variable. Included in the model were demographic and clinical data (age, sex, education year, disease duration), UPDRS part 3 score and subscores of each NMSS domain. The only predictor for NTD subtype was subscore of weight change domain in NMSS ([Table 4](#pone.0162254.t004){ref-type="table"}).

10.1371/journal.pone.0162254.t004

###### Multiple logistic regression analysis; predictors for PD patients with non-tremor dominant subtype.
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  Variables                                  OR (95% CI)             *p*
  ------------------------------------------ ----------------------- -------
  Age, per year increase                     1.002 (0.953--1.054)    0.923
  Sex (male as reference)                    0.540 (0.223--1.311)    0.173
  Education year, per year increase          0.981 (0.890--1.081)    0.698
  Disease duration, per month increase       0.994 (0.692--1.027)    0.713
  UPDRS part 3 score, per score increase     1.002 (0.951--1.055)    0.945
  **NMSS domains, per score increase**                               
  Cardiovascular including falls             1.040 (0.777--1.392)    0.793
  Sleep/fatigue                              0.897 (0.777--1.036)    0.140
  Mood/cognition                             0.973 (0.900--1.052)    0.491
  Perceptual problems/hallucinations         0.961 (0.583--1.583)    0.875
  Attention/memory                           1.158 (0.948--1.414)    0.150
  Gastrointestinal tract                     1.030 (0.885--1.199)    0.699
  Urinary                                    1.052 (0.950--1.165)    0.332
  Sexual function                            1.046 (0.964--1.134)    0.282
  Unexplained pain                           1.159 (0.866--1.515)    0.282
  Change in ability to taste or smell        1.055 (0.866--1.285)    0.594
  Weight change (not related to diet)        3.682 (1.143--11.865)   0.029
  Excessive sweat (not related to weather)   1.128 (0.850--1.497)    0.405

PD, Parkinson's disease; NMSS, Non-motor symptoms assessment scale.

Discussion {#sec010}
==========

This is the first study with systematic investigation of non-motor involvement between PD motor subtypes in drug-naïve PD patients. In our study, with multivariate regression analysis we demonstrated weight change was the only characteristic NMS in PD patients with NTD, and suggested weight change should be concerned even from early stage of PD. Considering that PD is a broad-spectrum disorder with clinical heterogeneity, each NMS can be easily affected by other motor and non-motor parkinsonian symptoms. Therefore, it is important to evaluate whole pattern of non-motor involvement in PD patients. Moreover, we enrolled drug-naïve PD patients, and eliminated the confounding effect from dopaminergic medications. Additionally, we also minimized possible confounding effect from the interrelation among each motor and non-motor parkinsonian symptoms by logistic regression analysis.

It is well-known that NMS are widely involved in PD patients from an early stage and some of NMS can even precede parkinsonian motor symptoms \[[@pone.0162254.ref001], [@pone.0162254.ref014]\]. We also demonstrated various NMS in PD patients, including pre-motor symptoms. When we compared between two subtypes, there was more non-motor involvements in PD patients with NTD subtype than those with NTD, even from early stage of PD. Among the various NMS, weight change was the characteristic NMS related with NTD subtype in PD patients.

Most of previous studies demonstrated weight loss in PD patients \[[@pone.0162254.ref010], [@pone.0162254.ref025], [@pone.0162254.ref026]\], while one study reported weight gain in early stage of PD \[[@pone.0162254.ref027]\]. Weight loss is known to be prominent with disease progression, but can be shown from early stage, and even several years before diagnosis \[[@pone.0162254.ref010], [@pone.0162254.ref025], [@pone.0162254.ref026]\]. In accordance with previous studies, we also found more weight change in early stage of PD patients, compared with normal controls.

The weight loss in PD is regarded as heterogeneous and multi-factorial symptom, and the pathophysiology of weight loss in PD patients is not clearly elucidated yet. In previous studies, various clinical features were known to contribute to weight loss, including poor appetite, hyposmia, intestinal hypomotility, depression, gastrointestinal side effects from medications, parkinsonism, dyskinesia, dementia and hallucination \[[@pone.0162254.ref026], [@pone.0162254.ref028], [@pone.0162254.ref029]\]. Considering we enrolled drug-naïve, early stage PD patients, our results suggest that parkinsonism of early or pre-motor stage, such as hyposmia, poor appetite or gastrointestinal hypomotility, can be closely associated with weight loss rather than those of advanced stage or medication side effects. Pathologic involvements in olfactory nerve, salivary glands and gastrointestinal tracts were already reported in pre-motor stage of PD patients, and also support our suggestion \[[@pone.0162254.ref030]\].

When we compared NMS between two PD subtypes, PD patients with NTD showed higher total NMSS score. In terms of each NMSS domains, there was significant difference only in subscore of weight loss domain. Previous study showed marginal significance in presence of tremor between PD patients with and without weight loss, although this study did not rule out medication effects \[[@pone.0162254.ref010]\]. In our study, to eliminate possible confounding effects from various interactions between weight change and other clinical factors \[[@pone.0162254.ref026], [@pone.0162254.ref028], [@pone.0162254.ref029]\], logistic regression analysis was done, and weight change was still the characteristic NMS in PD patients with NTD subtype. Therefore, weight change is characteristic NMS in PD patients with NTD regardless of other motor and NMS.

Interestingly, weight loss is known to be related with dementia, hallucination, and falling, which are common in PD patients with NTD subtype \[[@pone.0162254.ref026]\]. As already mentioned earlier, we suggest weight loss is regraded to be associated with early parkinsonian symptoms rather than late symptoms. Thus, characteristic non-motor involvement of NTD subtype starts from weight change, and evolves into diverse symptoms including perceptual and cognitive problems with disease progression.

Considering more severe motor symptoms in NTD subtype \[[@pone.0162254.ref005]\], PD patients with the NTD subtype show more both motor and non-motor involvement. Previous studies reported PD patients with NTD subtype have more degeneration of non-dopaminergic system as well as dopaminergic system \[[@pone.0162254.ref031], [@pone.0162254.ref032]\]. Further, more pathologic involvements were shown in NTD subtype patients \[[@pone.0162254.ref006]\]. Our results also support more clinical progression in PD patients with NTD subtype compared with those with TD subtype, even from early stage. In accordance with our results, recent study also reported weight loss is related with more severe neurodegeneration \[[@pone.0162254.ref033]\].

This study has some limitations. We designed to investigate whole NMS in drug-naïve PD patients, and did not check objective parameters for weight change, such as body mass index. However, unlike previous studies focusing on weight loss itself, we checked other NMS and minimized the interactions between weight loss and other motor and NMS. Second, we enrolled early stage PD patients, and we could not find any difference in NMS which is usually common in advanced stage of PD, such as cognitive or perceptual problems. In our study, PD patients with NTD subtype reported higher score of BDI and BAI than those with TD subtype, but there was no statistical significance. Considering NMS were reported to be prominent even from early stage of PD \[[@pone.0162254.ref001], [@pone.0162254.ref014]\], we focused on the early feature of non-motor involvement between PD subtypes, and we were able to avoid possible confounding effects by drug-naïve patients. Further study with follow-up data could be helpful to cover all these NMS. Lastly, we recruited a small number of subjects, especially for the normal control group. However, the primary objective of this study was to elucidate the non-motor involvement related with PD subtype, and enrolled sufficient number of drug-naïve, early PD patients. Additionally, we precisely evaluated non-motor involvements using the NMSS and other NMS-specific scales, and even with the small sample size, we were able to identify differences in NMS between PD patients and normal controls, and between PD subtypes.

In conclusion, our study demonstrated more non-motor involvement in PD patients with NTD subtype, and weight change as the characteristic NMS related with NTD subtype. Based on our results, we suggest that NTD subtype is associated with more widespread and severe clinico-pathologic involvement related to both motor and NMS even at an early stage.
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